Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[2].In Vitro: In human embryonic kidney 293 cells, (-)-Epigallocatechin gallate (EGCG) competitively inhibits OATP1A2-mediated uptake of Nadolol with a Ki value of 19.4 μM. With respect to Nadolol, the Km for OATP1A2 is 84 μM[2].In Vivo: In male OF1 mice bearing B16F10 tumor cells, blocking the neuroendocrine response through the administration of Nadolol (20 mg/kg) results in fewer and smaller pulmonary metastatic foci in subjects exposed to acute social stress.